Centre Caps Trade Margin at 30%, MRP May Plunge Up to 70% to Save Patients ₹2,500 Crore
_1732259259.jpg)
In a massive healthcare relief measure aimed at slashing catastrophic out-of-pocket medical expenses, the Central Government has decided to impose a 30 percent cap on trade margins across all non-scheduled anti-cancer formulations on Thursday, October 8, 2026. The intervention, reported by news agency PTI, tackles the inflated retail mark-ups traditionally added across supply tiers spanning bulk manufacturers, stockists, hospital distributors, and retail pharmacists. Officials project that rationalizing excessive distribution margins will directly push down the Maximum Retail Price (MRP) of several critical oncology therapies by up to 70 percent, providing immediate financial breathing room to lakhs of cancer patients and their families battling severe economic distress during protracted treatment cycles.
Universal Scope: Branded, Generic, Patented, and Imported Formulations Covered
The policy reform establishes a comprehensive pricing blanket across the entire non-scheduled oncology basket without selective exemptions:
Complete Category Coverage: The margin rationalization framework applies uniformly to both branded proprietary lines and generic non-scheduled oncology formulations available across domestic pharmacies.
Domestic and Imported Parity: The 30 percent trade margin ceiling covers medicines manufactured domestically within Indian pharmaceutical hubs as well as high-cost formulations imported from overseas biotech labs.
Patented and Off-Patent Applicability: Both patented novel therapies and off-patent molecules fall strictly under the new directive, curbing predatory distributor markups while preserving commercial supply availability across tertiary healthcare centers.
Patients to Save ₹2,500 Crore Annually: Relieving the Burden of Long-Term Oncology Care
The economic impact of the pricing cap is projected to deliver massive aggregate financial relief directly to household budgets:
Direct Annual Savings: Official government estimates calculate that the 30 percent trade margin cap will save cancer patients across India approximately ₹2,500 crore every year.
Mitigating Compounded Treatment Costs: With standard oncology regimens demanding months of continuous therapy alongside the steep expenses of surgery, chemotherapy infusions, and radiotherapy, lowering everyday pharmaceutical prices significantly reduces out-of-pocket expenditure.
Preventing Debt Crises: Lower baseline prices help prevent families from slipping into poverty or prematurely discontinuing life-saving regimens due to unsustainable prescription bills.
Expanding the 2019 Pilot: Replicating the Success of NPPA's First Trade Margin Rationalization
The broad-based intervention scales up a successful regulatory model pioneered by the National Pharmaceutical Pricing Authority (NPPA):
The 2019 Precedent: Back in February 2019, the NPPA implemented a pilot 30 percent trade margin cap restricted to 42 selected non-scheduled anti-cancer medications.
Proven Consumer Impact: Government tracking data revealed that the initial pilot triggered an average 50 percent price reduction across 526 commercial medicine brands, establishing the administrative feasibility of margin caps.
Scaling to the Entire Basket: Moving forward from the earlier selective list, the government has expanded the trade margin rationalization methodology across the entire spectrum of non-scheduled oncology pharmaceuticals.
Scheduled vs Non-Scheduled Drugs: How Pricing Mechanisms Function in India
Understanding the regulatory classification clarifies how Indian authorities regulate vital pharmaceutical costs:
Scheduled Drugs Under DPCO: Formulations listed under Schedule I of the Drugs (Prices Control) Order (DPCO) are subject to strict direct ceiling price fixing by the NPPA, which had already capped the ceiling rates for 131 scheduled anti-cancer drugs as of March 2026.
Non-Scheduled Framework: Non-scheduled medicines sit outside Schedule I and do not carry fixed statutory ceiling caps; instead, existing laws previously restricted manufacturers from hiking their MRP by more than 10 percent over any 12-month period.
Closing the Trade Margin Gap: By capping trade margins at 30 percent between the price to distributor (PTD) and retail MRP, the new policy prevents intermediaries from artificially inflating retail price tags on non-scheduled formulations, ensuring accessible cancer care nationwide.
_606024124_351x234.jpg)
_2026224331_351x234.jpg)
_56234847_351x234.jpg)
_881900406_351x234.jpg)
_1705927930_351x234.jpg)